Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0278488 (
metastatic breast cancer
)
7,812
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Carbonic anhydrase IX
(
CAIX
) is a hypoxia and HIF-1-inducible protein that regulates intra- and extracellular pH under hypoxic conditions and promotes tumor cell survival and invasion in hypoxic microenvironments. Interrogation of 3,630 human breast cancers provided definitive evidence of
CAIX
as an independent poor prognostic biomarker for distant metastases and survival. shRNA-mediated depletion of
CAIX
expression in 4T1 mouse
metastatic breast cancer
cells capable of inducing
CAIX
in hypoxia resulted in regression of orthotopic mammary tumors and inhibition of spontaneous lung metastasis formation. Stable depletion of
CAIX
in MDA-MB-231 human breast cancer xenografts also resulted in attenuation of primary tumor growth.
CAIX
depletion in the 4T1 cells led to caspase-independent cell death and reversal of extracellular acidosis under hypoxic conditions in vitro. Treatment of mice harboring
CAIX
-positive 4T1 mammary tumors with novel
CAIX
-specific small molecule inhibitors that mimicked the effects of
CAIX
depletion in vitro resulted in significant inhibition of tumor growth and metastasis formation in both spontaneous and experimental models of metastasis, without inhibitory effects on
CAIX
-negative tumors. Similar inhibitory effects on primary tumor growth were observed in mice harboring orthotopic tumors comprised of lung metatstatic MDA-MB-231 LM2-4(Luc+) cells. Our findings show that
CAIX
is vital for growth and metastasis of hypoxic breast tumors and is a specific, targetable biomarker for breast cancer metastasis.
...
PMID:Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. 2141 65
The sub-population of tumor cells termed 'cancer stem cells' (CSCs) possess the capability to generate tumors, undergo epithelial-mesenchymal transition (EMT) and are implicated in metastasis, making treatments to specifically target CSCs an attractive therapeutic strategy. Tumor hypoxia plays a key role in regulating EMT and cancer stem cell function.
Carbonic anhydrase IX
(
CAIX
) is a hypoxia-inducible protein that regulates cellular pH to promote cancer cell survival and invasion in hypoxic microenvironments and is a biomarker of poor prognosis for breast cancer metastasis and survival. Here, we demonstrate that inhibition of
CAIX
expression or activity with novel small-molecule inhibitors in breast cancer cell lines, or in primary
metastatic breast cancer
cells, results in the inhibition of breast CSC expansion in hypoxia. We identify the mTORC1 axis as a critical pathway downstream of
CAIX
in the regulation of cancer stem cell function.
CAIX
is also required for expression of EMT markers and regulators, as well as drivers of 'stemness', such as Notch1 and Jagged1 in isolated CSCs. In addition, treatment of mice bearing orthotopic breast tumors with
CAIX
-specific small-molecule inhibitors results in significant depletion of CSCs within these tumors. Furthermore, combination treatment with paclitaxel results in enhanced tumor growth delay and eradication of lung metastases. These data demonstrate that
CAIX
is a critical mediator of the expansion of breast CSCs in hypoxic niches by sustaining the mesenchymal and 'stemness' phenotypes of these cells, making
CAIX
an important therapeutic target for selectively depleting breast CSCs.
...
PMID:Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche. 2320 5